Video information:
Which additional CLL treatment options are available for patients who develop resistance to ibrutinib (Imbruvica)? In this “Ask the Expert” session, Dr. Michael Keating, a leading CLL expert from The University of Texas MD Anderson Cancer Center, explains alternative inhibitor approaches if a patient becomes resistant. Dr. Keating also explains the role of monoclonal antibodies.
Transcript:
Not available
Published By :
Patient Power
Date :
Oct 16, 2017
